Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...

Genialis krasID, the first AI/ML biomarker algorithm that can predict patient response and clinical benefit to KRAS ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains 29 different patent families ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...

To see if cryptic pockets were also present on other GTPases, Shokat and coworkers overlaid the sequence of these enzymes ...